惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

F
Fortinet All Blogs
爱范儿
爱范儿
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
B
Blog
WordPress大学
WordPress大学
Jina AI
Jina AI
GbyAI
GbyAI
aimingoo的专栏
aimingoo的专栏
N
Netflix TechBlog - Medium
腾讯CDC
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
阮一峰的网络日志
阮一峰的网络日志
The GitHub Blog
The GitHub Blog
V
Visual Studio Blog
Google DeepMind News
Google DeepMind News
月光博客
月光博客
博客园 - Franky
Y
Y Combinator Blog
MyScale Blog
MyScale Blog
大猫的无限游戏
大猫的无限游戏
Martin Fowler
Martin Fowler
雷峰网
雷峰网
小众软件
小众软件
H
Hackread – Cybersecurity News, Data Breaches, AI and More

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call Trans...
2026-04-24 · via All Articles on Seeking Alpha

Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call April 23, 2026 8:00 AM EDT

Company Participants

Thomas Schinecker - Group Chief Executive Officer
Alan Hippe - Chief Financial Officer
Teresa Graham - Chief Executive Officer of Roche Pharmaceuticals
Matthew Sause - Chief Executive Officer
Bruno Eschli - Head of Investor Relations

Conference Call Participants

James Gordon - Barclays Bank PLC, Research Division
Sachin Jain - BofA Securities, Research Division
Peter Verdult - BNP Paribas, Research Division
Sarita Kapila - Morgan Stanley, Research Division
Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division
Graham Glyn Parry - Citigroup Inc., Research Division
James Quigley - Goldman Sachs Group, Inc., Research Division
Simon Baker - Rothschild & Co Redburn, Research Division
Justin Steven Smith - Bernstein Institutional Services LLC, Research Division
Richard Vosser - JPMorgan Chase & Co, Research Division
Matthew Weston - UBS Investment Bank, Research Division
Steve Scala - TD Cowen, Research Division
Michael Leuchten - Jefferies LLC, Research Division
Rajesh Kumar - HSBC Global Investment Research

Presentation

Operator

My name is Henrik, and I'm the technical operator for today's call. Kindly note that the webinar is being recorded. [Operator Instructions] One last remark, if you would like to follow the presented slides on out as well, please feel free to go to roche.com/investors to download the presentation. At this time, it's my pleasure to introduce you to Thomas Schinecker, CEO Roche Group.

Thomas Schinecker
Group Chief Executive Officer

Thank you very much, and good morning and good afternoon to everyone. I'm very much excited to share our Q1 2026 results with you. Overall, a very strong performance in sales in the first quarter. And including there are some clinical and regulatory milestones that we have achieved.

Now let's start on the performance side. Q1 was strong with group sales at plus 6%, driven by pharma with plus 7%. Diagnostics grew plus 3% despite headwinds from the China